BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

489 related articles for article (PubMed ID: 18690968)

  • 1. QT prolongation and safety in the Indian population.
    Dabhi J; Mehta A
    Curr Drug Saf; 2007 Sep; 2(3):200-3. PubMed ID: 18690968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new biomarker--index of cardiac electrophysiological balance (iCEB)--plays an important role in drug-induced cardiac arrhythmias: beyond QT-prolongation and Torsades de Pointes (TdPs).
    Lu HR; Yan GX; Gallacher DJ
    J Pharmacol Toxicol Methods; 2013; 68(2):250-259. PubMed ID: 23337247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug-induced QT Interval Prolongation in the Intensive Care Unit.
    Etchegoyen CV; Keller GA; Mrad S; Cheng S; Di Girolamo G
    Curr Clin Pharmacol; 2017; 12(4):210-222. PubMed ID: 29473523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular predictors of drug-induced prolongation of the QT interval.
    Dilaveris PE
    Curr Med Chem Cardiovasc Hematol Agents; 2005 Apr; 3(2):105-18. PubMed ID: 15853698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does terfenadine-induced ventricular tachycardia/fibrillation directly relate to its QT prolongation and Torsades de Pointes?
    Lu HR; Hermans AN; Gallacher DJ
    Br J Pharmacol; 2012 Jun; 166(4):1490-502. PubMed ID: 22300168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug-induced QTC prolongation dangerously underestimates proarrhythmic potential: lessons from terfenadine.
    Hondeghem LM; Dujardin K; Hoffmann P; Dumotier B; De Clerck F
    J Cardiovasc Pharmacol; 2011 May; 57(5):589-97. PubMed ID: 21346598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Torsade de pointes induced by terfenadine in a patient with long QT syndrome.
    Koh KK; Rim MS; Yoon J; Kim SS
    J Electrocardiol; 1994 Oct; 27(4):343-6. PubMed ID: 7815014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Drug induced QT prolongation].
    Altmann D; Eggmann U; Ammann P
    Wien Klin Wochenschr; 2008; 120(5-6):128-35. PubMed ID: 18365152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sex differences in ventricular repolarization: from cardiac electrophysiology to Torsades de Pointes.
    Abi-Gerges N; Philp K; Pollard C; Wakefield I; Hammond TG; Valentin JP
    Fundam Clin Pharmacol; 2004 Apr; 18(2):139-51. PubMed ID: 15066127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The canine Purkinje fiber: an in vitro model system for acquired long QT syndrome and drug-induced arrhythmogenesis.
    Gintant GA; Limberis JT; McDermott JS; Wegner CD; Cox BF
    J Cardiovasc Pharmacol; 2001 May; 37(5):607-18. PubMed ID: 11336111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Minimizing the risks associated with QTc prolongation in people with schizophrenia. A consensus statement by the Cardiac Safety in Schizophrenia Group].
    Ames D; Camm J; Cook P; Falkai P; Gury C; Hurley R; Johnson G; Piepho R; Vieweg V;
    Encephale; 2002; 28(6 Pt 1):552-62. PubMed ID: 12506268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antipsychotic-related QTc prolongation, torsade de pointes and sudden death.
    Haddad PM; Anderson IM
    Drugs; 2002; 62(11):1649-71. PubMed ID: 12109926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiac actions of antihistamines.
    Woosley RL
    Annu Rev Pharmacol Toxicol; 1996; 36():233-52. PubMed ID: 8725389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonclinical proarrhythmia models: predicting Torsades de Pointes.
    Lawrence CL; Pollard CE; Hammond TG; Valentin JP
    J Pharmacol Toxicol Methods; 2005; 52(1):46-59. PubMed ID: 15975832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug-induced long QT syndrome and torsade de pointes.
    Morissette P; Hreiche R; Turgeon J
    Can J Cardiol; 2005 Aug; 21(10):857-64. PubMed ID: 16107909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolongation of the QT interval and cardiac arrhythmias associated with cisapride: limitations of the pharmacoepidemiological studies conducted and proposals for the future.
    Layton D; Key C; Shakir SA
    Pharmacoepidemiol Drug Saf; 2003; 12(1):31-40. PubMed ID: 12616845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Association of Proton Pump Inhibitors and QT Interval Prolongation in Critically Ill Patients.
    Fan W; Liu H; Shen Y; Hong K
    Cardiovasc Drugs Ther; 2024 Jun; 38(3):517-525. PubMed ID: 36625987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effects of clinically available drugs on the repolarization process of the heart assessed by the in vivo canine models].
    Sugiyama A
    Nihon Yakurigaku Zasshi; 2003 Jun; 121(6):393-400. PubMed ID: 12835533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Lengthening of QT interval by antipsychotic drugs].
    Haverkamp W; Deuschle M
    Nervenarzt; 2006 Mar; 77(3):276, 278-80, 282-4 passim. PubMed ID: 16052325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms and risks of electrocardiographic QT interval prolongation when using antipsychotic drugs.
    Vieweg WV
    J Clin Psychiatry; 2002; 63 Suppl 9():18-24. PubMed ID: 12088172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.